To include your compound in the COVID-19 Resource Center, submit it here.

Avanir surges on AD agitation data

Investors added $1 billion in market cap to Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) on Monday after the company's AVP-923 dextromethorphan/quinidine met the primary endpoint

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE